3 terminated, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow SF 1126: new trials by email Literature Review of SF 1126 trials Research Report on SF 1126
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma SF1126, Nivolumab - Advanced Hepatocellular Carcinoma | Phase 1 | Terminated | SignalRX Pharmaceuticals, Inc. | 7 | 2017-03-27 | 2022-05-18 |
| SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes SF1126 - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Terminated | Ezra Cohen | 1 | 2016-11-01 | 2018-07-11 |
| SF1126 for Patients With Relapsed or Refractory Neuroblastoma SF1126 - Neuroblastoma | Phase 1 | Terminated | New Approaches to Neuroblastoma Therapy Consortium | 4 | 2015-07-09 | 2018-08-20 |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors SF1126 - Advanced or Metastatic Solid Tumors, Cancer | Phase 1 | Completed | Semafore Pharmaceuticals | 44 | 2007-04-01 | 2013-06-13 |
Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Ezra Cohen (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · Semafore Pharmaceuticals (1) · SignalRX Pharmaceuticals, Inc. (1)
United States (4)
Donald L Durden, MD, PhD (1) · Ezra Cohen, MD (1) · Steven DuBois, MD (1)